A new groundbreaking study has recently identified the link between the long-standing mystery in autoimmune disease: ...

The physical, emotional and financial toll of lupus can be invisible to those who don’t live with this disease. Lupus symptoms affect each person differently, and it can be difficult for those without ...

Wednesday, December 24 📍 Where: Southlake Mall – Lower Level, right in front of the Food Court & Cinnabon. 1000 Southlake Mall, Morrow, GA 30260 ...

Veteran’s Day is a day to officially pause and honor the men and women who have served in the United States armed forces. For some veterans, the battles don’t end when their time in the military is ...

New results from a study of a drug called Gazyva (obinutuzumab) showed that it significantly reduced disease activity in adults with systemic lupus erythematosus (SLE). The drug was developed by ...

Sex and intimacy are deeply personal, and lupus can complicate matters. During our recent webinar, Lupus & You: After Dark - A Conversation on Sexual Health and Intimacy, we discussed how lupus can ...

Purpose of Study: The purpose of this study is to establish the safety and potential effectiveness of investigational FT819 in participants with moderate to severe systemic lupus erythematosus (SLE) ...

The Lupus Foundation of America works with medical experts and people with lupus and their care partners to offer clear, easy-to-use educational materials and toolkits to help you navigate every step ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...

A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus Erythematosus (SLE). Preliminary data suggests that CAR-T therapy may ...

Fate Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the lupus treatment candidate FT819.